Microbot Medical® Files 10-Q and Highlights Key Third Quarter Operating Achievements
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Microbot Medical (MBOT) reported third-quarter revenue of $72,000 as LIBERTY procedure utilization increased despite a sequential sales decline. Revenue fell from $241,000 in the second quarter, while procedures rose 44%. Customer accounts increased to 12 from 10, and all customers that exhausted initial inventory reordered multiple systems.
Gross margin was negative, with cost of goods sold rising 24% sequentially, largely from an inventory write-down. Manufacturing costs per newly produced unit declined. The company believes cost initiatives and a planned second manufacturing line could enable positive gross margin during 2027. Quarter-end cash, cash equivalents and marketable securities totaled approximately $62 million. Following Israeli regulatory approval, Microbot signed a three-year exclusive distribution agreement with Medtechnica and expects initial orders in the fourth quarter of 2026.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointQuarter-end cash, cash equivalents and marketable securities totaled approximately $62 million.
- Moderate pointLIBERTY procedure utilization rose 44% in the third quarter compared with the second quarter.
- Moderate pointCustomer accounts increased to 12 from 10 at the end of the second quarter.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Microbot believes cost initiatives and a planned second manufacturing line could enable positive gross margin during 2027.
- Moderate pointIsraeli regulatory approval preceded a three-year exclusive distribution agreement with Medtechnica to market and sell LIBERTY.
6 minor points
- Minor point100% of customers that exhausted initial inventory reordered multiple systems.
- Minor pointManufacturing cost per system produced during the third quarter declined compared with previous quarters.
- Minor point. Forward-looking: it has not happened yet and may not happen.Microbot expects initial Israeli distribution orders in the fourth quarter of 2026.
- Minor point. Forward-looking: it has not happened yet and may not happen.Sales territories expanded by two to ten; Microbot plans 12 by the end of 2026.
- Minor pointNew patents in the U.S., Japan, China and Canada brought issued patents to 44.
- Minor pointMicrobot successfully completed its ISO certificate surveillance audit.
Negative
- Moderate pointThird-quarter revenue declined sequentially to $72,000 from $241,000 in the second quarter.
- Moderate pointThird-quarter gross margin was negative; systems sold primarily reflected earlier, higher-cost production.
- Moderate pointMultiple potential accounts remain in hospital approval processes that take approximately 4–6 months.
- Minor pointCost of goods sold increased 24% sequentially, largely because of an inventory write-down.
- Minor point. Forward-looking: it has not happened yet and may not happen.Further manufacturing savings depend partly on the second manufacturing line being completed as planned.
News Explained
At
Sources and calculations
- Microbot Medical third-quarter 2026 fundamentals (2026-09-30)
- Available liquidity against the last reported quarterly operating outflow, in days at that rate ($2,292,000 + $59,536,000) / ($5,407,000 / 92) = 1052 days
Details
Market move: MBOT -29.45% vs previous close. 3Q26 earnings report
On Nov 16, the day this news came out, the latest delayed price for MBOT is 29.45% below the previous close. Our momentum scanner has recorded 12 alerts for this stock so far that day. The latest delayed price is $0.69. Relative volume is exceptionally heavy at 32.8x what this stock usually trades by this time of day.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Q3 revenue
- $72,000
- Quarter ended September 30, 2026; compared with $241,000 in Q2
- Cost of goods sold
- Increased 24%
- Compared with Q2
- Procedure utilization
- Up 44%
- Q3 compared with Q2
- Cash, cash equivalents and marketable securities
- Approximately $62 million
- At the end of Q3
- Customer accounts
- 12
- At Q3 end, compared with 10 at Q2 end
- Repeat orders
- 100%
- Current customers who exhausted initial inventory reordered multiple systems
Historical Context
-
Three-year exclusive agreement anticipated initial orders during Q4 2026.
-
Q2 revenue and customer counts each grew more than 100% versus Q1.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
10-q regulatory
net realizable value financial
fifo financial
fda-cleared regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Company continues to expand commercial presence in the U.S. while it progresses international market entry and opportunities
Increased the number of health systems and hospital sites using LIBERTY, while utilization of the LIBERTY System rose
HINGHAM, Mass., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, today announced that it has filed its Quarterly Report on Form 10-Q for the third quarter ended September 30, 2026, with the Securities and Exchange Commission.
The Company reported revenue of
The Company reports that
During the third quarter, the Company experienced increased procedure utilization within existing accounts.
As anticipated, the Company reported a negative gross margin in the third quarter. Cost of goods sold increased by
Other Third Quarter and Recent Highlights
- The Company ended the third quarter with cash, cash equivalents and marketable securities of approximately
$62 million , enabling the Company to continue executing its commercial strategy in the U.S. and internationally. - Utilization (number of procedures) of the LIBERTY Endovascular Robotic System in Q3 is up
44% compared to Q2. - Academic center in North Carolina adopted the LIBERTY System, becoming the Company’s second health system in the state of North Carolina to use the system.
- The Company’s first West Coast customer, located in California, is also its first Office-Based Lab customer.
- The Company ended the third quarter with 12 customer accounts, compared to 10 customer accounts at the end of the second quarter. Additionally, the Company added two sales territories during the third quarter, expanding to ten, and plans to increase to 12 sales territories by the end of 2026.
- Customers have used LIBERTY in a variety of procedure types, including Prostatic Artery Embolization (PAE), Y-90 Radioembolization, Genicular Artery Embolization (GAE) and Uterine Artery Embolization (UAE), which the Company believes supports its positioning of the LIBERTY System as a platform for multiple peripheral intervention procedures.
- Following regulatory approval from the Israeli Ministry of Health's AMAR Division, the Company entered into a three-year exclusive distribution agreement with Medtechnica Ltd. to market and sell the LIBERTY System in Israel. The Company currently expects to receive initial orders under the agreement during the fourth quarter of 2026.
- During and after the third quarter, the Company received new patents in the U.S., Japan, China and Canada. As of this press release, the Company held 44 issued patents and 49 pending patent applications.
- The Company successfully completed the ISO certificate surveillance audit.
“In less than six months since the full market release of the LIBERTY System, we are encouraged by the quality of customers we have added, and we believe their repeat purchases reflect their satisfaction with LIBERTY,” commented Harel Gadot, CEO, President and Chairman. “While revenue this quarter in part reflected the seasonality of the third quarter and the sales cycle process associated with the VAC, we believe the progress we made this year positions us for several potential milestones over the coming months in the U.S. and the international markets in which we operate.”
LIBERTY is the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, and it is designed for precise vascular navigation while aiming to reduce radiation exposure and physical strain.
About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Microbot’s LIBERTY® Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency and safety. Backed by a strong intellectual property portfolio and a commitment to innovation, Microbot is driving the future of endovascular care.
Learn more at www.microbotmedical.com and connect on LinkedIn and X.
Safe Harbor
Statements relating to future financial and/or operating results, revenue, gross margin, cost reductions, manufacturing capacity, sales territory expansion, customer orders and re-orders, distributor orders, future adoption of products, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “contemplates,” “continues,” “could,” “forecasts,” “intends,” “may,” “might,” “possible,” “potential,” “predicts,” “projects,” “should,” “would,” “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially, including, without limitation, market conditions; risks inherent in the commercialization of the LIBERTY® Endovascular Robotic System, including the Company’s limited commercial history and revenue; the length and outcome of hospital Value Analysis Committee and other purchasing processes and the resulting variability in quarterly revenue; the Company’s ability to retain customers and obtain re-orders; the Company’s ability to reduce costs, complete its second manufacturing line and achieve positive gross margin; the Company’s ability to hire and retain sales personnel; the performance of distributors; competition; reimbursement and hospital capital budgets; the Company’s need for additional capital and its cash resources; risks in the development of future versions of or applications for the system; uncertainty in the results of regulatory pathways and regulatory approvals; uncertainty resulting from political, social and geopolitical conditions; disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries; and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical® can be found under the heading “Risk Factors” in Microbot Medical’s Annual Report on Form 10-K for the year ended December 31, 2025, its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 and other periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Forward-looking statements speak only as of the date of this press release, and readers are cautioned not to place undue reliance on them. Microbot Medical® disclaims any intent or obligation to update these forward-looking statements, except as required by law.
Contacts:
IR@microbotmedical.com
Media@microbotmedical.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How did Microbot Medical's third-quarter 2026 revenue and LIBERTY utilization compare with the second quarter?
Microbot reported revenue of $72,000, down from $241,000 in the second quarter, while LIBERTY procedure utilization increased 44%. Customer accounts increased to 12 at quarter-end from 10 at the end of the second quarter.
When does Microbot Medical expect to achieve positive gross margin?
Microbot believes it could achieve positive gross margin during 2027 through ongoing cost reductions and the planned addition of a second manufacturing line, if completed as planned. Manufacturing cost per system produced in the third quarter declined compared with previous quarters.
Why did Microbot Medical's third-quarter 2026 revenue decline despite higher LIBERTY utilization?
Microbot attributed the revenue decline to factors including customer re-order timing and lower summer activity. Multiple potential accounts also remained in hospital Value Analysis Committee reviews, an approval process taking approximately 4–6 months, following the full market release approximately six months earlier.